Aquestive Therapeutics, Inc. says the FDA accepted its new application for Anaphylm™, with a decision expected by March 16, 2027.

AQST · Aquestive Therapeutics, Inc.

The AI's read

This moves Anaphylm farther through the FDA review process and gives investors a date for a decision. The FDA has not approved it, so sales from this product are not assured. This is favorable progress, but the outcome still depends on the FDA's decision.